GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Taisho Pharmaceutical Holdings Co Ltd (TSE:4581) » Definitions » 3-Year EBITDA Growth Rate

Taisho Pharmaceutical Holdings Co (TSE:4581) 3-Year EBITDA Growth Rate : 4.10% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Taisho Pharmaceutical Holdings Co 3-Year EBITDA Growth Rate?

Taisho Pharmaceutical Holdings Co's EBITDA per Share for the three months ended in Dec. 2023 was 円55.41.

During the past 12 months, Taisho Pharmaceutical Holdings Co's average EBITDA Per Share Growth Rate was -51.90% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 4.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -6.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was -1.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Taisho Pharmaceutical Holdings Co was 16.70% per year. The lowest was -16.70% per year. And the median was 0.20% per year.


Competitive Comparison of Taisho Pharmaceutical Holdings Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Taisho Pharmaceutical Holdings Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taisho Pharmaceutical Holdings Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Taisho Pharmaceutical Holdings Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Taisho Pharmaceutical Holdings Co's 3-Year EBITDA Growth Rate falls into.



Taisho Pharmaceutical Holdings Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Taisho Pharmaceutical Holdings Co  (TSE:4581) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Taisho Pharmaceutical Holdings Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Taisho Pharmaceutical Holdings Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Taisho Pharmaceutical Holdings Co (TSE:4581) Business Description

Traded in Other Exchanges
Address
3-24-1 Takada, Toshima-ku, Tokyo, JPN, 170-8655
Taisho Pharmaceutical Holding Co Ltd is a specialty and generic drug manufacturing company. The company maintains two operational segments, Self-Medication and Prescription Pharmaceuticals. The vast majority of Taisho's revenue is derived from its Self-Medication segment. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities. The vast majority of sales are generated by sales to external customers in Japan.

Taisho Pharmaceutical Holdings Co (TSE:4581) Headlines

No Headlines